3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Lung Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Carcinoma, Small Cell
1
Interventions
pembrolizumab
21
lenvatinib
8
Paclitaxel
5
patritumab deruxtecan
3
enfortumab vedotin
2
belzutifan
2
Tretinoin
2
Surgical Procedures, Operative
2
Oxaliplatin
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
Carboplatin
2
Capecitabine
2
tremelimumab
1
trametinib
1
poly ICLC
1
epacadostat
1
efineptakin alfa
1
durvalumab
1
dabrafenib
1
Ramucirumab
1
Radiotherapy
1
Radiosurgery
1
Radiation
1
Pemetrexed
1
Levoleucovorin
1
Immunotherapy
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Histamine Antagonists
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled